相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan
Masahiro Kobayashi et al.
JOURNAL OF GASTROENTEROLOGY (2019)
Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study
Kazuomi Ueshima et al.
CANCERS (2019)
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
Jorge A. Marrero et al.
HEPATOLOGY (2018)
Up-to-seven criteria as a useful predictor for tumor downstaging to within Milan criteria and Child-Pugh grade deterioration after initial conventional transarterial chemoembolization
Yutaka Yasui et al.
HEPATOLOGY RESEARCH (2018)
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Peter R. Galle et al.
JOURNAL OF HEPATOLOGY (2018)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Lenvatinib May Drastically Change the Treatment Landscape of Hepatocellular Carcinoma
Masatoshi Kudo
LIVER CANCER (2018)
Outcomes of patients (pts) with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE): Global OPTIMIS final analysis.
Markus Peck-Radosavljevic et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Extremely High Objective Response Rate of Lenvatinib: Its Clinical Relevance and Changing the Treatment Paradigm in Hepatocellular Carcinoma
Masatoshi Kudo
LIVER CANCER (2018)
Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial
Masatoshi Kudo et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2018)
Subclassification of patients with intermediate-stage (Barcelona Clinic Liver Cancer stage-B) hepatocellular carcinoma using the up-to-seven criteria and serum tumor markers
Haruki Kimura et al.
HEPATOLOGY INTERNATIONAL (2017)
Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma
Kenji Ikeda et al.
JOURNAL OF GASTROENTEROLOGY (2017)
Hepatocellular Carcinoma: Therapeutic Guidelines and Medical Treatment
Masatoshi Kudo et al.
LIVER CANCER (2017)
Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update
Masao Omata et al.
HEPATOLOGY INTERNATIONAL (2017)
Lenvatinib in Advanced Hepatocellular Carcinoma
Masatoshi Kudo
LIVER CANCER (2017)
Beneficial Effect of Maintaining Hepatic Reserve during Chemotherapy on the Outcomes of Patients with Hepatocellular Carcinoma
Takeshi Terashima et al.
LIVER CANCER (2017)
Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis
Atsushi Hiraoka et al.
DIGESTIVE DISEASES (2017)
Impact of Tumor Factors on Survival in Patients with Hepatocellular Carcinoma Classified Based on Kinki Criteria Stage B2
Tadaaki Arizumi et al.
DIGESTIVE DISEASES (2017)
Time to Transcatheter Arterial Chemoembolization Refractoriness in Patients with Hepatocellular Carcinoma in Kinki Criteria Stages B1 and B2
Tadaaki Arizumi et al.
DIGESTIVE DISEASES (2017)
Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma
Jordi Bruix et al.
GASTROENTEROLOGY (2016)
Subclassification of BCLC B Stage Hepatocellular Carcinoma and Treatment Strategies: Proposal of Modified Bolondi's Subclassification (Kinki Criteria)
Masatoshi Kudo et al.
DIGESTIVE DISEASES (2015)
Validation of a Modified Substaging System (Kinki Criteria) for Patients with Intermediate-Stage Hepatocellular Carcinoma
Tadaaki Arizumi et al.
ONCOLOGY (2015)
Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma
Tadaaki Arizumi et al.
LIVER CANCER (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Efficacy of Sorafenib in Intermediate-Stage Hepatocellular Carcinoma Patients Refractory to Transarterial Chemoembolization
Sadahisa Ogasawara et al.
ONCOLOGY (2014)
JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan
Masatoshi Kudo et al.
LIVER CANCER (2014)
A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours
D. S. Boss et al.
BRITISH JOURNAL OF CANCER (2012)
Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines
Kenichi Takayasu et al.
JOURNAL OF HEPATOLOGY (2012)
Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions
Luigi Bolondi et al.
SEMINARS IN LIVER DISEASE (2012)
Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients with Advanced Solid Tumors
Kazuhiko Yamada et al.
CLINICAL CANCER RESEARCH (2011)
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
Riccardo Lencioni et al.
SEMINARS IN LIVER DISEASE (2010)
Comparison of the effects of the kinase inhibitors imatinib, sorafenib, and transforming growth factor-beta receptor inhibitor on extravasation of nanoparticles from neovasculature
Mitsunobu R. Kano et al.
CANCER SCIENCE (2009)
Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization
B. Wang et al.
ACTA RADIOLOGICA (2008)
Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): The role of angiogenesis and invasiveness
Adriana Sergio et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2008)
Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase
Junji Matsui et al.
CLINICAL CANCER RESEARCH (2008)
E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition
Junji Matsui et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Antiangiogenic therapy enhances the efficacy of transcatheter arterial embolization for hepatocellular carcinomas
Hongchi Jiang et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis
Hashem B. El-Serag et al.
GASTROENTEROLOGY (2007)
A comparison of propensity score methods: A case-study estimating the effectiveness of post-AMI statin use
PC Austin et al.
STATISTICS IN MEDICINE (2006)
Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
RK Jain
SCIENCE (2005)
Angiogenesis in cancer and other diseases
P Carmeliet et al.
NATURE (2000)
分享论文
